कंपनी का अवलोकन
Tenax Therapeutics, Inc. operates as a development-stage pharmaceutical company focused on creating novel cardiopulmonary therapies within the United States market. The firm specializes in the advancement of specific drug candidates, including TNX-101, TNX-102, and TNX-103 (levosimendan), which have successfully completed phase II clinical trials aimed at treating patients suffering from pulmonary hypertension. This entity functions within the broader healthcare sector, specifically under the biotechnology industry, where it leverages research and development to address critical unmet medical needs in cardiac and respiratory care. The company maintains a relatively small operational scale, employing 14 individuals to execute its scientific mission. With a total market capitalization of $258.82 million, the firm represents a mid-sized public entity in the biotech landscape, yet it reports no annual revenue figures available for calculation. This specific valuation profile, combined with a complete lack of reported revenue, indicates that the company is currently in a capital-intensive growth phase where value is derived from intellectual property and clinical progress rather than immediate commercial sales, positioning it as a high-risk, high-potential asset typical of early-stage biopharmaceutical ventures.
वित्तीय स्वास्थ्य
The reported financial statements for Tenax Therapeutics, Inc. show a net income of $-52,599,000 for the trailing twelve months, while revenue and EBITDA figures are not available for public disclosure. The substantial negative net income in the absence of reported revenue highlights a cost structure dominated by research, development, and clinical trial expenses that far exceed any current commercial income generation. The company generates a free cash flow of $-18,441,624, which signifies a continuous burn rate where cash outflows for operations and capital expenditure are outpacing any incoming cash, indicating a reliance on external financing to sustain operations. Analysis of the three primary margins reveals that the gross margin, operating margin, and profit margin are all recorded at 0.0%, a common characteristic for development-stage biotechnology companies that have not yet achieved significant commercial product sales. The balance sheet demonstrates a conservative financial posture with total cash reserves of $97.56 million contrasted against zero total debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of debt. Furthermore, the current ratio stands at 14.56, which indicates an extremely strong short-term liquidity position, suggesting the company possesses ample current assets to cover its current liabilities many times over. Return on equity is reported at -55.6% and return on assets at -35.1%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate losses rather than profits, reflecting the typical financial dynamics of a firm still in the clinical development pipeline.
मूल्यांकन आकलन
Valuation metrics for Tenax Therapeutics, Inc. present a complex picture where the P/E ratio (TTM) is not applicable and the forward P/E is listed as -10.29, a figure that implies negative expected earnings and precludes standard profitability-based valuation models. The price-to-book ratio is 6.58, indicating that the market values the company's equity at a significant premium relative to its net book value, a valuation often driven by the potential value of its intangible assets and pipeline rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not available for calculation due to the lack of reported revenue and EBITDA data, which limits the ability to perform traditional multiple comparisons with established peers. The stock has experienced significant price volatility over the last year, trading between a 52-week high of $18.38 and a 52-week low of $4.63. Without a specific current price provided in the source facts to calculate a precise percentage deviation, the stock's position within this range remains a function of recent market sentiment regarding its clinical pipeline. The beta value is 1.19, which indicates that the stock's price volatility is approximately 19% higher than the broader market, suggesting that the asset class is more sensitive to market movements than the average large-cap equity.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year rates are not available for public disclosure, which prevents a direct comparison of the pace at which earnings are growing relative to revenue. Since the company does not pay dividends, the dividend yield is not applicable and the payout ratio is 0.0%, meaning the firm retains all of its earnings or utilizes its cash reserves to fund its research and development activities rather than distributing income to shareholders. This reinvestment strategy is standard for development-stage pharmaceutical companies, where capital is directed toward advancing clinical trials for TNX-101, TNX-102, and TNX-103 to achieve market approval. The overall growth and income profile of Tenax Therapeutics, Inc. is characterized by a complete absence of current profitability and dividend distribution, relying entirely on the potential future commercialization of its cardiopulmonary therapy portfolio to drive future financial performance.